HSD17B13 based on human genetic studies holds great promise for drug development as a potential therapeutic target for NASH and related liver diseases, especially in the absence of a specific drug treatment for NAFLD. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatohepatitis.